The blue light eyewear market is projected to reach $5.8 billion by 2034. Consumer demand is accelerating at 8–10% annually. 94% of consumers cite scientific validation as the most important factor in their purchase decision.
Yet the category faces a credibility crisis. The 2023 Cochrane systematic review of 17 randomized controlled trials found that existing blue light filtering lenses showed no benefit for eye strain, sleep quality, or macular health.
The reason is not that the science of spectral photobiology is wrong. The reason is that the products were never designed to apply it correctly.
Five structural gaps define the current category — and one platform is engineered to close all five simultaneously.